Brain MRI for Suspected Dementia
Yes, you should obtain structural brain imaging—preferably MRI without contrast—for suspected dementia, as it is recommended in almost all patients to exclude treatable causes and identify patterns of atrophy that support specific diagnoses. 1
Primary Imaging Recommendation
MRI without IV contrast is the standard of care for dementia evaluation when available and not contraindicated. 1 If MRI is unavailable or contraindicated (e.g., pacemakers, severe claustrophobia, metallic implants), CT head without contrast should be obtained instead. 2, 1
Why MRI is Preferred
MRI demonstrates regional atrophy patterns that correlate with tau deposition and serve as valid biomarkers for Alzheimer's disease (AD), including early volume loss in the entorhinal cortex and hippocampus. 2, 3
MRI detects vascular contributions to cognitive impairment, including white matter hyperintensities on FLAIR sequences and microhemorrhages on susceptibility-weighted imaging, which are critical for identifying vascular dementia and cerebral amyloid angiopathy. 1, 4
MRI excludes treatable structural lesions such as subdural hematomas, brain tumors, infarcts, and neuroinflammatory or infectious processes that can mimic dementia. 1
High-field 3T MRI with specialized sequences allows detection of early structural changes and differentiation between dementia subtypes with greater precision than CT. 3
When CT is Acceptable
CT head without contrast is appropriate when MRI is not feasible, as it can still identify treatable structural lesions (subdural hematomas, masses) and demonstrate hippocampal atrophy patterns seen in AD. 2 However, CT has lower sensitivity than MRI for detecting subtle atrophy patterns and vascular changes. 4
Critical Exclusions
Do NOT routinely use contrast-enhanced imaging (MRI or CT with IV contrast) for initial dementia evaluation, as there is no supporting literature for this approach in typical presentations. 2
Advanced Imaging Considerations
While structural MRI is the foundation, additional imaging may be warranted in specific scenarios:
Amyloid PET/CT is appropriate for atypical presentations (young-onset, rapid progression, nonamnestic symptoms) or when diagnosis remains uncertain after structural imaging, and is required before initiating anti-amyloid monoclonal antibody therapy. 2
FDG-PET/CT has higher diagnostic accuracy than MRI for differentiating AD from non-AD dementias (sensitivity 95%, specificity 73%) and can distinguish AD from frontotemporal dementia based on hypometabolism patterns. 2
Common Pitfalls to Avoid
Do not dismiss imaging findings as "age-related" in patients with cognitive symptoms. Cerebral atrophy, white matter changes, or microhemorrhages should be clearly delineated and correlated clinically, not routinely attributed to aging. 1
Ensure proper MRI protocol: Request three-dimensional T1-weighted volumetric sequences for quantitative atrophy assessment, plus FLAIR and susceptibility-weighted imaging for vascular pathology detection. 4
Consider clinical context: In bed-bound, non-communicative patients with longstanding severe dementia, neuroimaging may not be warranted unless there are compelling clinical reasons. 1